KRYS · Insider Trading
Krystal Biotech, Inc. Common Stock
Every open-market purchase and sale reported by KRYS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Julian S Gangolli | Director | A | +1,658 deriv. | — |
| 2026-09-16 | Everett Rand Sutherland | Director | A | +1,658 deriv. | — |
| 2026-09-16 | Christopher Mason | Director | A | +1,658 deriv. | — |
| 2026-09-16 | Daniel Janney | Director | A | +1,658 deriv. | — |
| 2026-09-16 | Catherine Mazzacco | Director | A | +1,658 deriv. | — |
| 2026-09-16 | Dino A Rossi | Director | A | +1,658 deriv. | — |
| 2026-09-04 | Suma Krishnan | President, R&D | Sell | −25,000 | −$8.98M |
| 2026-09-04 | Krish S Krishnan | President and CEO | Sell | −25,000 | −$8.98M |
| 2026-08-14 | Dino A Rossi | Director | MIXED | −28,691 | −$8.23M |
| 2026-06-26 | John Charles Thomas | EVP, General Counsel | MIXED | — | −$168.02K |
| 2026-06-05 | Suma Krishnan | President, R&D | Sell | −25,000 | −$7.70M |
| 2026-06-05 | Krish S Krishnan | President and CEO | Sell | −25,000 | −$7.70M |
| 2026-05-27 | John Charles Thomas | EVP, General Counsel | Sell | −642 | −$193.90K |
| 2026-03-06 | Suma Krishnan | President, R&D | Sell | −25,000 | −$6.58M |
| 2026-03-06 | Krish S Krishnan | President and CEO | Sell | −25,000 | −$6.58M |
| 2026-03-03 | Daniel Janney | Director | Sell | −11,803 | −$3.25M |
| 2026-03-03 | Kathryn Romano | Chief Accounting Officer | MIXED | +3,798 | −$1.17M |
| 2026-03-03 | Krish S Krishnan | President and CEO | MIXED | +36,641 | −$8.43M |
| 2026-03-03 | Suma Krishnan | President, R&D | MIXED | +36,641 | −$8.43M |
| 2026-02-26 | Daniel Janney | Director | MIXED | −22,266 | −$16.06M |
| 2026-02-23 | Dino A Rossi | Director | MIXED | — | −$4.79M |
| 2026-02-11 | Kathryn Romano | Chief Accounting Officer | MIXED | −750 | −$2.61M |
| 2025-12-05 | Suma Krishnan | President, R&D | MIXED | −55,000 | −$11.01M |
| 2025-12-05 | Krish S Krishnan | President and CEO | MIXED | −55,000 | −$11.01M |
| 2025-07-16 | Krish S Krishnan | President and CEO | Sell | −35,873 | −$5.40M |
| 2025-07-16 | Suma Krishnan | President, R&D | Sell | −35,873 | −$5.40M |
| 2025-07-11 | Suma Krishnan | President, R&D | Sell | −14,127 | −$2.12M |
| 2025-07-11 | Krish S Krishnan | President and CEO | Sell | −14,127 | −$2.12M |
| 2025-06-30 | Daniel Janney | Director | A | +5,000 deriv. | — |
| 2025-06-30 | Dino A Rossi | Director | A | +5,000 deriv. | — |
| 2025-06-30 | Everett Rand Sutherland | Director | A | +5,000 deriv. | — |
| 2025-06-30 | Catherine Mazzacco | Director | A | +5,000 deriv. | — |
| 2025-06-30 | Julian S Gangolli | Director | A | +5,000 deriv. | — |
| 2025-06-30 | Christopher Mason | Director | A | +5,000 deriv. | — |
| 2025-03-13 | Krish S Krishnan | President and CEO | Sell | −50,000 | −$8.89M |
| 2025-03-13 | Suma Krishnan | President, R&D | Sell | −50,000 | −$8.89M |
| 2025-02-28 | Kathryn Romano | Chief Accounting Officer | MIXED | +3,696 | −$1.57M |
| 2025-02-28 | Krish S Krishnan | President and CEO | MIXED | +33,623 | −$7.84M |
| 2025-02-28 | Suma Krishnan | President, R&D | MIXED | +33,623 | −$7.84M |
| 2024-12-13 | Krish S Krishnan | President and CEO | Sell | −50,000 | −$8.24M |
| 2024-12-13 | Suma Krishnan | President, R&D | Sell | −50,000 | −$8.24M |
| 2024-09-13 | Dino A Rossi | Director | G | −5,000 | — |
| 2024-09-13 | Krish S Krishnan | President and CEO | Sell | −50,000 | −$9.89M |
| 2024-09-13 | Suma Krishnan | President, R&D | Sell | −50,000 | −$9.89M |
| 2024-07-01 | Julian S Gangolli | Director | A | +5,000 deriv. | — |
| 2024-07-01 | Daniel Janney | Director | A | +5,000 deriv. | — |
| 2024-07-01 | Christopher Mason | Director | A | +5,000 deriv. | — |
| 2024-07-01 | Catherine Mazzacco | Director | A | +5,000 deriv. | — |
| 2024-07-01 | Everett Rand Sutherland | Director | A | +5,000 deriv. | — |
| 2024-07-01 | Dino A Rossi | Director | A | +5,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Krish S Krishnan | President and CEO | 1,400,726 | $429.32M |
| Suma Krishnan | President, R&D | 1,356,274 | $415.70M |
| Daniel Janney | Director | 74,036 | $22.69M |
| Dino A Rossi | Director | 53,135 | $16.29M |
| Kathryn Romano | Chief Accounting Officer | 23,356 | $7.16M |
| John Charles Thomas | EVP, General Counsel | 1,000 | $306.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KRYS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.